Alpinvest Partners B.v. buys $3,854,550 stake in SAGE Therapeutics Inc (SAGE)

SAGE Therapeutics Inc (SAGE) : Alpinvest Partners B.v. scooped up 26,359 additional shares in SAGE Therapeutics Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 10, 2016. The investment management firm now holds a total of 105,000 shares of SAGE Therapeutics Inc which is valued at $3,854,550.SAGE Therapeutics Inc makes up approximately 6.44% of Alpinvest Partners B.v.’s portfolio.

Other Hedge Funds, Including , Blackrock Fund Advisors boosted its stake in SAGE in the latest quarter, The investment management firm added 250,382 additional shares and now holds a total of 1,037,928 shares of SAGE Therapeutics Inc which is valued at $38,102,337. SAGE Therapeutics Inc makes up approx 0.01% of Blackrock Fund Advisors’s portfolio.Ubs Asset Management Americas Inc boosted its stake in SAGE in the latest quarter, The investment management firm added 242,064 additional shares and now holds a total of 331,056 shares of SAGE Therapeutics Inc which is valued at $12,381,494. SAGE Therapeutics Inc makes up approx 0.01% of Ubs Asset Management Americas Inc’s portfolio.State Board Of Administration Of Florida Retirement System boosted its stake in SAGE in the latest quarter, The investment management firm added 3,494 additional shares and now holds a total of 10,316 shares of SAGE Therapeutics Inc which is valued at $453,904.Swiss National Bank boosted its stake in SAGE in the latest quarter, The investment management firm added 7,600 additional shares and now holds a total of 40,700 shares of SAGE Therapeutics Inc which is valued at $1,791,207.Harvey Capital Management Inc reduced its stake in SAGE by selling 1,360 shares or 8.04% in the most recent quarter. The Hedge Fund company now holds 15,545 shares of SAGE which is valued at $689,887. SAGE Therapeutics Inc makes up approx 0.33% of Harvey Capital Management Inc’s portfolio.

SAGE Therapeutics Inc opened for trading at $35.92 and hit $36.69 on the upside on Friday, eventually ending the session at $36.45, with a gain of 0.19% or 0.07 points. The heightened volatility saw the trading volume jump to 9,10,709 shares. Company has a market cap of $1,170 M.

Many Wall Street Analysts have commented on SAGE Therapeutics Inc. H.C. Wainwright Initiated SAGE Therapeutics Inc on Jun 23, 2016 to “Buy”, Price Target of the shares are set at $56.Chardan Capital Markets Initiated SAGE Therapeutics Inc on May 24, 2016 to “Sell”, Price Target of the shares are set at $18.

SAGE Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat life-threatening rare central nervous system (CNS) disorders. The Company’s lead product candidate in its status epilepticus (SE) program is SAGE-547. SAGE-689 and SAGE-217 are two additional product candidates in its pipeline. The Company has submitted investigational new drug (IND) for SAGE-547 for the treatment of SRSE with the United States Food and Drug Administration. SAGE-547 is an allosteric modulator of both synaptic and extra-synaptic GABAA receptors. SAGE-217 is a neuroactive steroid that acts as a positive allosteric modulator of synaptic and extra-synaptic GABAA receptor subtypes. SAGE-689 is being developed as an adjunctive IV therapy for the treatment of status epilepticus patients.

Leave a Reply

SAGE Therapeutics Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on SAGE Therapeutics Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.